Patients with high-grade serous epithelial ovarian, tubal or primary peritoneal cancers research hub

NIRAPK : Study of the relationships between pharmacokinetic properties (PK) and hematological toxicity of niraparib in ovarian cancer

This study looks at how a cancer drug called niraparib (Zejula) affects patients with ovarian cancer. Researchers want to understand why some patients experience side effects like changes in their blood or kidney problems, by studying how the body handles the drug.